Literature DB >> 12023614

Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation.

Maria T Millan1, Judith A Shizuru, Petra Hoffmann, Sussan Dejbakhsh-Jones, John D Scandling, F Carl Grumet, Jane C Tan, Oscar Salvatierra, Richard T Hoppe, Samuel Strober.   

Abstract

BACKGROUND: Rodents and dogs conditioned with total-lymphoid irradiation (TLI), with or without antithymocyte globulin (ATG), have been shown to develop mixed chimerism and immune tolerance without graft-versus-host disease (GVHD) after the infusion of major histocompatability complex (MHC)-mismatched donor bone marrow cells given alone or in combination with an organ allograft.
METHODS: Four human leukocyte antigen (HLA)-mismatched recipients of living donor kidney transplants were conditioned with TLI and ATG posttransplantation and infused with cyropreserved donor granulocyte colony-stimulating factor (G-CSF) "mobilized" hematopoietic progenitor (CD34+) cells (3-5x10(6) cells/kg) thereafter. Maintenance prednisone and cyclosporine dosages were tapered, and recipients were monitored for chimerism, GVHD, graft function, T-cell subsets in the blood, and antidonor reactivity in the mixed leukocyte reaction (MLR).
RESULTS: Three of the four patients achieved multilineage macrochimerism, with up to 16% of donor-type cells among blood mononuclear cells without evidence of GVHD. Prolonged depletion of CD4+ T cells was observed in all four patients. Rejection episodes were not observed in the three macrochimeric recipients, and immunosuppressive drugs were withdrawn in the first patient by 12 months. Prednisone was withdrawn from a second patient at 9 months, and cyclosporine was tapered thereafter.
CONCLUSIONS: Multilineage macrochimerism can be achieved without GVHD in HLA-mismatched recipients of combined kidney and hematopoietic progenitor transplants. Conditioning of the host with posttransplant TLI and ATG was nonmyeloablative and was not associated with severe infections. Recipients continue to be studied for the development of immune tolerance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023614     DOI: 10.1097/00007890-200205150-00005

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  62 in total

1.  Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants.

Authors:  J D Scandling; S Busque; S Dejbakhsh-Jones; C Benike; M Sarwal; M T Millan; J A Shizuru; R Lowsky; E G Engleman; S Strober
Journal:  Am J Transplant       Date:  2012-03-08       Impact factor: 8.086

2.  An act of tolerance.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

Review 3.  B cells and transplantation tolerance.

Authors:  Allan D Kirk; Nicole A Turgeon; Neal N Iwakoshi
Journal:  Nat Rev Nephrol       Date:  2010-08-24       Impact factor: 28.314

4.  Evidence for kidney rejection after combined bone marrow and renal transplantation despite ongoing whole-blood chimerism in rhesus macaques.

Authors:  S K Ramakrishnan; A Page; A B Farris; K Singh; F Leopardi; K Hamby; S Sen; A Polnett; T Deane; M Song; L Stempora; E Strobert; A D Kirk; C P Larsen; L S Kean
Journal:  Am J Transplant       Date:  2012-05-29       Impact factor: 8.086

5.  Microchimerism maintains deletion of the donor cell-specific CD8+ T cell repertoire.

Authors:  Weldy V Bonilla; Markus B Geuking; Peter Aichele; Burkhard Ludewig; Hans Hengartner; Rolf M Zinkernagel
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

Review 6.  Translating transplantation tolerance in the clinic: where are we, where do we go?

Authors:  M Goldman; K Wood
Journal:  Clin Exp Immunol       Date:  2009-01-22       Impact factor: 4.330

Review 7.  Induction of tolerance through mixed chimerism.

Authors:  David H Sachs; Tatsuo Kawai; Megan Sykes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

8.  Murine cytomegalovirus dissemination but not reactivation in donor-positive/recipient-negative allogeneic kidney transplantation can be effectively prevented by transplant immune tolerance.

Authors:  Anil Dangi; Shuangjin Yu; Frances T Lee; Melanie Burnette; Jiao-Jing Wang; Yashpal S Kanwar; Zheng J Zhang; Michael Abecassis; Edward B Thorp; Xunrong Luo
Journal:  Kidney Int       Date:  2020-02-21       Impact factor: 10.612

Review 9.  Cell therapeutic approaches to immunosuppression after clinical kidney transplantation.

Authors:  Christian Morath; Anita Schmitt; Florian Kälble; Martin Zeier; Michael Schmitt; Flavius Sandra-Petrescu; Gerhard Opelz; Peter Terness; Matthias Schaier; Christian Kleist
Journal:  Pediatr Nephrol       Date:  2017-02-23       Impact factor: 3.714

10.  H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease.

Authors:  Bita Sahaf; Yang Yang; Sally Arai; Leonard A Herzenberg; Leonore A Herzenberg; David B Miklos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.